[This corrects the article DOI: 10.1016/j.chmed.2019.08.002.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476738 | PMC |
| http://dx.doi.org/10.1016/j.chmed.2021.04.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to "Physiological energetics of selectively bred oysters (Crassostrea hongkongensis) under marine heatwaves" [Mar. Environ. Res. 204 (2025) 106871].
Mar Environ Res
December 2024
Guangdong Provincial Key Laboratory of Aquatic Animal Disease Control and Healthy Culture, Fishery College, Guangdong Ocean University, Zhanjiang, China; Oyster Industrial Technology Institute of Zhanjiang, Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, China. Electronic address:
Corrigendum to "A multiple attribute group decision making model based on 2-tuple linguistic Pythagorean fuzzy Dombi aggregation operators for optimal selection of potential global suppliers" [Heliyon 10 (14) (July 2024) e34570].
Heliyon
October 2024
Department of Mathematics, College of Science, Qassim University, Buraydah, 51452, Saudi Arabia.
[This corrects the article DOI: 10.1016/j.heliyon.
View Article and Find Full Text PDFCorrigendum: Sparse testing designs for optimizing predictive ability in sugarcane populations.
Front Plant Sci
November 2024
Agronomy Department, University of Florida, Gainesville, FL, United States.
[This corrects the article DOI: 10.3389/fpls.2024.
View Article and Find Full Text PDFCorrigendum to "Na-mediated carbon nitride realizing CO photoreduction with selectivity modulation" [J. Colloid Interface Sci. 670 (2024) 348-356].
J Colloid Interface Sci
March 2025
College of Environmental Science and Engineering, Institute of Technology for Carbon Neutralization, Yangzhou University, Yangzhou 225009, PR China. Electronic address:
Corrigendum: CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder.
Front Pharmacol
October 2024
Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, Italy.
[This corrects the article DOI: 10.3389/fphar.2024.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!